9 registrations that name lactobacillus reuteri as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 9 registrations
Status
Phase
1US sites across 1 state
1
2 to 4
5 to 19
20 or more
All 9 registrations
RecruitingNCT07347743
Preventive Effect of a Dietary Supplement With Two Probiotic Limosilactobacillus Reuteri Strains on Excessive Crying and Colic in Healthy Newborns.
No phase
Universitair Ziekenhuis Brussel
About 768 people
Started Jan 31, 2026
In plain words A study of lactobacillus reuteri in people 1 day to 14 days, run by Universitair Ziekenhuis Brussel. It plans to enroll about 768 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 1 day to 14 days; healthy volunteers accepted. Conditions: Colic; Healthy Infants; Eczema Atopic Dermatitis.
Infant is born at the maternity ward of UZ Brussel with a gestational age of ≥37 weeks.
Infant is healthy at the time of pre-examination.
Infant is aged between 1 and 14 days old at the time of inclusion.
Legal guardian(s) are able and willing to follow the study instructions
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Two probiotic Limosilactobacillus reuteri strains; Placebo
Registered summary
This study aims to demonstrate that a dietary supplement, which contains two strains of the probiotic L. reuteri is safe, well tolerated and able to reduce the incidence of colic and excessive crying/fussiness in healthy infants. Additionally, the study aims to investigate if children with this probiotic supplement have better stool characteristics and a more beneficial composition of the fecal and skin flora than children given a placebo during the first 3 months of life.
Where, as registered
No US site; Belgium (1).
RecruitingNCT07498712
Effect of L. Reuteri LM1063 on Sleep Health Improvement
No phase
Lactomason Co., Ltd.
About 80 people
Started Jul 14, 2025
In plain words A study of lactobacillus reuteri in people 19 to 65, run by Lactomason Co., Ltd.. It plans to enroll about 80 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 19 to 65; healthy volunteers accepted. Conditions: Sleep Quality; Sleep Wake Disorders.
Healthy male or female adults aged 19 to 65.
Pittsburgh Sleep Quality Index (PSQI) score of 5 or higher.
Voluntarily agreed to participate and signed the informed consent form.
The exclusion criteria are on the listing.
What it tests, as registered
Limosilactobacillus reuteri LM1063; Placebo
Registered summary
Purpose: The purpose of this clinical trial is to evaluate the efficacy and safety of Limosilactobacillus reuteri LM1063 on improving sleep health in healthy adults. Based on the microbiota-gut-brain axis, this study aims to scientifically analyze whether the supplementation of this specific probiotic strain can enhance sleep quality. Methodology: This is a randomized, double-blind, placebo-controlled, single-center clinical trial. A total of 80 participants (40 in the test group and 40 in the control group) will be enrolled. Participants in the test group will consume 500 mg of L. The full summary is on the listing.
Where, as registered
No US site; South Korea (1).
RecruitingNCT07443410
Microbiological and Clinical Effects of Pre- and Probiotics in Non-Surgical Periodontal Therapy
No phase
University Hospital Heidelberg
About 60 people
Started Oct 25, 2024
In plain words A study of lactobacillus reuteri in people 18 and older, run by University Hospital Heidelberg. It plans to enroll about 60 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older; healthy volunteers accepted. Conditions: Periodontitis, Adult; Periodontitis (Stage 3); Periodontitis Stage IV.
Age ≥ 18 years
Stage III or IV periodontitis (localized or generalized)
Ability to provide informed consent
Written informed consent including data protection consent
Periodontitis is a prevalent chronic inflammatory disease driven by a dysbiotic oral biofilm and a dysregulated host immune response. Standard non-surgical periodontal therapy (NSPT) is primarily mechanical and, in selected cases, may be accompanied by antiseptics or systemic antibiotics. Targeted modulation of the oral microbiome ("microbiome engineering") is currently not part of routine periodontal care due to limited high-quality evidence. The full summary is on the listing.
Where, as registered
No US site; Germany (1).
RecruitingNCT07029360
Effectiveness of Coenzyme Q10 and Probiotics in Periodontal Therapy During Pregnancy
No phase
University of Pavia
About 40 people
Started Jul 1, 2025
In plain words A study of lactobacillus reuteri in female participants 18 and older, run by University of Pavia. It plans to enroll about 40 people at 1 site, none in the US.
This randomized controlled clinical trial aims to evaluate the effectiveness of adjunctive coenzyme Q10 and probiotic supplementation (Limosilactobacillus reuteri Prodentis®) in improving periodontal health in pregnant women undergoing non-surgical periodontal therapy. Forty participants will be randomly assigned to two groups: the test group will receive professional oral hygiene every three months along with a coenzyme Q10-based toothpaste and daily probiotic supplementation; the control group will follow the same protocol without probiotics. The full summary is on the listing.
Where, as registered
No US site; Italy (1).
Not yet recruitingNCT07462767
Precision Microbiota Interventions for Senoreduction Trial
Phase 1 and 2
Louisiana State University Health Sciences Center in New Orleans
About 160 people
Starts Oct 1, 2026 (estimated)
In plain words A Phase 1 and 2 study of lactobacillus reuteri in people 40 and older, run by Louisiana State University Health Sciences Center in New Orleans. It plans to enroll about 160 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 40 and older. Conditions: HIV Infections; Alcohol Drinking; Aging; Immunosenescence.
Age ≥40 years
People with HIV
Recent alcohol use defined as ≥42 grams in the prior week and positive urine ethyl glucuronide (EtG)
The exclusion criteria are on the listing.
What it tests, as registered
Limosilactobacillus reuteri; Blueberry extract
Registered summary
People with HIV who drink alcohol are at increased risk for accelerated aging biology, including increased immune senescence. This randomized, double-blind, crossover clinical trial evaluates two generally recognized as safe (GRAS) microbiota-targeted interventions on immune senescence biomarkers.
Where, as registered
1 US site in 1 state.
Not yet recruitingNCT07870824
A Study to Investigate the Effect of Probiotics (L. Reuteri DSM 17938 and L. Reuteri DSM 33633) on Symptoms of Viral Upper Respiratory Tract Infections in Children
No phase
Milosevits Gergely
About 194 people
Starts Oct 12, 2026 (estimated)
In plain words A study of lactobacillus reuteri in people 4 to 17, run by Milosevits Gergely. It plans to enroll about 194 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 4 to 17. Conditions: Virus Diseases in Children.
Children with symptoms of upper respiratory tract infection (coughing/fever/sneezing/runny or congested nose/pharynx pain)
Any gender
Age from 4 years to 17 years
Signing a informed consent form by at least one parent, foster parent or guardian after patient information and by children aged over 6 years
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Probiotics (L. reuteri DSM 17938 and L. reuteri DSM 33633); Placebo
Registered summary
This study investigates the effect of Lactobacillus reuteri probiotic strains (DSM 17938 and L. reuteri DSM 33633) on symptoms of viral upper-respiratory tract infections in children.
Where, as registered
No US site; Hungary (1).
Not yet recruitingNCT06026228
Effects of Probiotic Oral Intake on Plasma Chlordecone (Kepone) Concentrations in Individuals Environmentally Exposed to Pesticide in Martinique.
No phase
University Hospital Center of Martinique
About 100 people
Starts Apr 2024 (estimated)
In plain words A study of lactobacillus reuteri in people 18 and older, run by University Hospital Center of Martinique. It plans to enroll about 100 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Chlordecone (Kepone) Toxicity.
Male or female, 18 years of age or older
Seen in clinical toxicology consultation at the CHU of Martinique during the study period
With an initial chlordeconemia > 1μg/L on a test less than 1 month old at the time of study inclusion
Affiliated to a social security scheme
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Limosilactobacillus reuteri; Placebo
Registered summary
The CHLOR-DETOX study is a single-centre, double-blind, prospective, interventional, controlled, exploratory pilot study on subjects environmentally exposed to the organochlorine pesticide (kepone or chlordecone, CLD) in the French Caribbean (Martinique island). To our best knowledge, it is the first clinical trial in such subjects evaluating the potential effect of oral probiotic intake (Limosilactobacillus reuteri) on the reduction of CLD plasma levels (chlordeconemia) and fecal excretion, thus concurring to the reduction of CLD toxicity in study subjects.
Where, as registered
No US site; Martinique (1).
Not yet recruitingNCT07306481
The Efficacy of Preoperative Oral Administration of Lactobacillus Reuteri Combined With Preoperative Neoadjuvant/Conversion Immunotherapy in Patients With Primary Resectable Liver Cancer
No phase
Fujian Cancer Hospital
About 40 people
Starts Dec 20, 2025 (estimated)
In plain words A study of lactobacillus reuteri in people 18 to 75, run by Fujian Cancer Hospital. It plans to enroll about 40 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 75. Conditions: HCC - Hepatocellular Carcinoma.
Understanding and voluntarily signing the informed consent form for this study;
Age≥18 years and ≤75 years; gender not restricted;
Histologically (pathologically), cytologically, or radiologically confirmed hepatocellular carcinoma (HCC);
Patients who require preoperative immune checkpoint inhibitor (ICI) combination therapy followed by potentially curative hepatectomy;
9 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Dietary Supplement: L. reuteri DSM 17938
Registered summary
On the basis of previous studies, this study intends to explore the efficacy of preoperative oral administration of Lactobacillus reuteri (Lr) combined with preoperative neoadjuvant/conversion therapy in patients with primary resectable hepatocellular carcinoma (HCC). We hypothesize that this combination represents a novel, microbiota-based therapeutic strategy to facilitate perioperative hepatic recovery and improve long-term survival outcomes. This study is an open-label, randomized, blank-controlled clinical trial. The full summary is on the listing.
Where, as registered
No sites listed yet.
Not yet recruitingNCT07624656
Functionally Enhanced Limosilactobacillus Reuteri Probiotic Preparation in Elderly Patients With Functional Bowel Disorders
No phase
Maanshan Shiqiye Hospital
About 30 people
Starts Jun 2026 (estimated)
In plain words A study of lactobacillus reuteri in people 50 to 65, run by Maanshan Shiqiye Hospital. It plans to enroll about 30 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 50 to 65. Conditions: Functional Gastrointestinal Disorders.
Functional constipation;
Irritable bowel syndrome (IBS);
Functional abdominal pain syndrome;
Participants must have clear intestinal dysfunction-related symptoms such as abdominal pain, abdominal distension, difficulty in defecation, or changes in bowel habits, with organic gastrointestinal diseases excluded by clinical evaluation.
This is a single-center, open-label, single-arm interventional study designed to evaluate the effects of a functionally enhanced Limosilactobacillus reuteri probiotic preparation on intestinal immunity, gut microbiota balance, and intestinal function in elderly patients with functional bowel disorders. Participants aged 50-65 years with functional bowel disorders, including functional constipation, irritable bowel syndrome, or functional abdominal pain syndrome diagnosed according to Rome IV criteria, will receive the probiotic intervention. The full summary is on the listing.
Where, as registered
No sites listed yet.
ClinicalTrials.gov lists 28 open registrations for this search, including ones where lactobacillus reuteri is not a study arm or that are past the 9 we keep. Search them on ClinicalTrials.gov (opens in new tab).